MondegarAI
BML Capital Management, LLC

Q1 2026 · 13F-HR

BML Capital Management, LLCholdings as filed

Filed 2026-05-06 · accession 0001754960-26-000359

$155.8M
Reported value
16
Positions
2026-03-31
Period end
View analyzed profile →PRO

The Brief · BML Capital Management, LLC · Q1 2026

AI · grounded in 13F

BML Capital Management, LLC established a new position in TLYS valued at $8.7M. The fund also opened new stakes in KHC for $2.8M and JANX for $2.1M. To fund these moves, the manager closed positions in CVNA with a $2.0M reduction, as well as TSLA and LSTA. Additionally, the fund increased its holding in OM by 250.2%.

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
00461U105ACRSACLARIS THERAPEUTICS INC$53.4M34.3%14,250,000CommonNONE
04683R106AVIRATEA PHARMACEUTICALS INC$38.0M24.4%7,058,657CommonNONE
68403P203ORMPORAMED PHARMACEUTICALS INC$10.8M6.91%3,167,231CommonNONE
886885102TLYSTILLYS INC$8.7M5.59%2,150,000CommonNONE
690145206OMOUTSET MED INC$7.3M4.69%1,902,201CommonNONE
69353Y103PMVPPMV PHARMACEUTICALS INC$6.6M4.24%5,320,000CommonNONE
143130102KMXCARMAX INC$6.4M4.14%155,000CommonNONE
49372L2092KZ0KEZAR LIFE SCIENCES INC$5.3M3.43%720,787CommonNONE
45783C200TILINSTIL BIO INC$5.3M3.42%645,600CommonNONE
87612E106TGTTARGET CORP$4.5M2.92%37,500CommonNONE
500754106KHCKRAFT HEINZ CO$2.8M1.80%125,000CommonNONE
47103J105JANXJANUX THERAPEUTICS INC$2.2M1.38%154,961CommonNONE
729139105PLRXPLIANT THERAPEUTICS INC$1.9M1.25%1,546,137CommonNONE
G23549101CNTBCONNECT BIOPHARMA HLDGS LTD$1.1M0.69%408,887CommonNONE
45175G207IMAIMAGENEBIO INC$1.0M0.64%200,730CommonNONE
931142103WMTWALMART INC$329,1380.21%335PUTNONE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.